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Biomolecules from Cerastes cerastes venom have been purified and characterized. Two phospholipases isolated from
Cerastes cerastes venom share 51% of homology. CC2-PLA2 exhibits antiplatelet activity that blocks coagulation.
CCSV-MPase, a non-hemorrhagic Zn2+-metalloproteinase, significantly reduced the plasmatic fibrinogen level and
hydrolyzes only its Bβ chain. Serine proteinases such as RP34, afaâcytin and CC3-SPase hydrolyze the fibrinogen and
are respectively α, αβ and αβ fibrinogenases. In deficient human plasma, afaâcytin replaces the missing factors VIII
and IX, and activates purified human factor X into factor Xa. It releases serotonin from platelets and directly
aggregates human (but not rabbit) blood platelets. RP34 proteinase also had no effect on both human and rabbit
blood platelet aggregation. CC3-SPase revealed a pro-coagulant activity. However, the insolubility of the obtained
clot indicates that CC3-SPase does not activate factor XIII. In addition, CC3-SPase clotting activity was carried out
with human plasmas from volunteer patients deficient in clotting factors. Results showed that CC3-SPase shortens
clotting time of plasma deficient in factors II and VII but with weaker clotting than normal plasma. The clotting time
of plasma deficient in factor II is similar to that obtained with normal plasma; suggesting that CC3-SPase is able to
replace both factors IIa and VII in the coagulation cascade and thus could be involved in the blood clotting process
via an extrinsic pathway. These results imply that CC3-SPase and afaâcytin could repair hemostatic abnormalities
and may replace some factors missing in pathological deficiency. Afaâcytin also exhibits α fibrinase property similar
to a plasmin-like proteinase. Despite its thrombin-like characteristics, afaâcytin is not inhibited by plasmatic
thrombin inhibitors. The procoagulant properties of afaâcytin might have potential clinical applications.
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Serine proteases and phospholipases A2 isolated from
snake venoms act on the hemostatic system as procoa-
gulants, anticoagulants, pro- or anti-platelet aggregants.
Some of these isolated molecules, mainly from Viperidae
venoms, are used in diagnosis or treatment of thrombotic
diseases and ischemic heart disease. Metalloproteinases
can cause hemorrhage after accidental or experimental en-
venomation. However, some of these metalloproteinases
are directly involved in the clotting of blood as they can
act on fibrinogen and/or fibrin; they are called in this case
fibrino(geno)lytic metalloproteinases. Their fibrinolytic ac-
tivity makes them potent inhibitors of blood coagulation.
Phospholipase A2 exert their anticoagulant effect by their* Correspondence: flaraba@hotmail.com
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distribution, and reproduction in any mediumability to inhibit platelet aggregation due to their high affin-
ity to bind to activated factor Stewart (FXa). All these bio-
logical effects based on their direct involvement in
hemostasis, let consider these molecules as potential tools
or biomarkers in blood diseases.Review
Viperidae and Crotalidae venoms are rich sources of
hydrolytic enzymes and produce a complex pattern of
clinical and toxic effects such as coagulation disorders,
hemorrhage and necrosis [1-10]. Some of venom com-
ponents act at various stages of the coagulation cascade.
These components perform antagonistic functions,
whilst some of them act synergistically. Therefore, the
venom toxicity cannot be attributed to only one compo-
nent [11]. However, most venom components produce
beneficial effects when they act alone [12]. Snake venom
also contains non-protein components including citrate,Med Central Ltd. This is an Open Access article distributed under the terms of
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concentrations of free amino acids and lipids [13-15].
Phospholipases A2 (PLA2s) represent more than 10%
of the dry weight of the snake venoms from which they
are isolated. PLA2s isolated from Viperidae venoms con-
sist of 125–130 amino acid residues cross-linked by
seven disulfide bonds which confer stability on the mol-
ecule and are calcium-dependant [16]. In addition to
their hydrolytic activity, PLA2s may display many other
activities, such as edematous, neurotoxic, cardiotoxic,
hemolytic, convulsive, antiplatelet, antitumoral and
anticoagulant properties. Based on their anticoagulant
activity, PLA2s can be clinically useful against throm-
botic diseases and for the diagnosis and treatment of
hemostatic disorders [17]. The anticoagulant activity is
due to their ability to inhibit platelet aggregation
through factor Xa (FXa) blockade. Based on their direct
involvement in the hemostatic cascade, PLA2 could also
be used as tools or biomarkers in blood diseases.
Metalloproteinases found in Viperidae venoms may
cause local hemorrhaging following accidental or experi-
mental intradermal or subcutaneous injection of venom
[18]. Some of them are known to display fibrino
(geno)lytic activity. Fibrino(geno)lytic metalloproteinases
dissolve fibrin clots and prevent clot formation by
hydrolyzing fibrinogen, thus enhancing the toxic effect of
hemorrhagic metalloproteinases, giving rise to patho-
logical bleeding [19]. However, similar to PLA2s,
metalloproteinases could be clinically useful against
thrombotic diseases thanks to their potential use in la-
boratory tests or as therapeutic agents [20,21]. These pro-
teinases may be useful for investigating the mechanisms of
blood coagulation and platelet aggregation [11,12].
In addition to their beneficial effects, venom molecules
are the cause of health problems after snake envenom-
ation. Annually, more than 100,000 deaths are recorded
worldwide, including 20,000 on African continent, while
400,000 victims retain severe and permanent functional
sequelae [3]. Epidemiological data estimate envenom-
ation cases at more than 5 million per year, with a mor-
tality rate of 2.5%. In tropical Africa, Viperidae bites are
responsible for 90% of envenomations [22]. Currently,
the only available specific treatment against viper en-
venomation is immunotherapy [23-26]. Indications for
this therapy, its mode of administration and type of anti-
body preparation in the form of F (ab’)2 or Fab still need
to be elucidated [27-30]. Improvement of this treatment
requires knowledge of the kinetic distribution of venom
in vascular and tissue compartments.
Cerastes cerastes venom is a mixture of various pro-
teins with broad biological and physiological activities;
most of them are proteinases while some have been well
characterized. Most of these proteins act on blood co-
agulation, including PLA2, the thrombin-like enzymesRP34 and afaâcytin, anticoagulant protease fraction,
aggregant serine protease, hemorrhagic metalloprotei-
nase CcH1, and the non-hemorrhagic metalloproteinase
CCSV-MPase [11,12,31-35]. In this paper, we report
pharmacological activity of biomolecules isolated from
Cerastes cerastes on hemostasis process.
Biochemical properties of biomolecules and their
proteomic identification
Several molecules from Cerastes cerastes venom act on
hemostasis, such as RP34, a serine proteinase which
consists of two subunits of 48.5 kDa [32]. Another serine
proteinase, a thrombin-like molecule denominated afaâ-
cytin, was purified and characterized [11]. Afaâcytin pre-
sents caseinolytic, arginine-esterase and amidase activities.
It is a homodimeric proteinase with two subunits, alpha
and beta, which have the same apparent molecular mass
(40.0 kDa for each unit) and are indistinguishable in the
absence of reduction or/and deglycosylation [11]. Both α
and β chains are N-glycosylated. The two chains present
the same N-terminal sequence (20 residues) which is simi-
lar to the sequence of other proteinases isolated from
snake venom.
Three molecules – CC2-PLA2, CCSV-MPase and
CC3-SPase – were characterized by proteomic analysis.
Results showed some sequence similarity with other
homologous enzymes isolated from several venoms
[11,12,17,31-34]. CC2-PLA2, another PLA2 found in the
same venom, presents 51% sequence homology with a
previously purified molecule from the same venom by
Laraba-Djebari et al. [32] (accession number in NCBInr
is gi |129506|), i.e. 61 out of 120 amino acid residues are
common to the two PLA2s [31]. The peptide sequence
of the new PLA2 was obtained by alignment with se-
quences of other venom PLA2s. Some snake venom
proteinases were identified sharing sequence homology
with CCSV MPase, four of which belonged to the
metalloproteinase family (Group III snake venom
metalloproteinase and Zn+2-metalloproteinase disinte-
grin) [17]. Three of these proteins corresponded to
Cerastes vipera venom and the others to venom proteins
of different snake species [17].
All of these proteins were identified with at least two
unique specific peptides and presented similarities with
the purified CCSV-MPase. Previous studies showed that
CCSV-MPase, characterized by SDS-PAGE analysis,
could be classified as a member of the high-molecular-
mass metalloproteinase family, due to its molecular
mass estimated at 70 kDa in both reducing and non-
reducing electrophoresis conditions [12]. Furthermore,
the partial amino acid sequence of CCSV-MPase was
identified by MALDI-TOF MS/MS analysis. Based on
its molecular mass and partial amino acid sequence,
CCSV-MPase may be classified in the P-III class of
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with cystein-rich domains.
It is well established that some venom components
have beneficial effects when acting in isolation. Cerastes
cerastes venom is a mixture of protein components with
multiple actions including coagulation [11,32,36,37].
These proteins may induce hemorrhage and capillary
permeability disorders, through their disintegrin domain
or related proteins that disrupt primary hemostasis by
acting on platelet adhesion. Thus, a single molecule can
be endowed with several activities. The structural differ-
ences between proteins, natural factors of hemostasis, as
well as the multiplicity of target components of the same
venom, are elements that could explain the efficiency of
partial immunotherapy [15]. Fibrinogenases (serine
proteinases or metalloproteinases) are widespread in
Viperidae venoms. They hydrolyze fibrinogen and/or
degrade the fibrin clot, enhancing the effect of
hemorrhagic metalloproteinases that give rise to patho-
logical bleeding.
Coagulant and fibrinogenolytic activities of isolated
molecules
Fibrinogen is a glycoprotein of 340 kDa with three poly-
peptide chains; Aα (67 kDa), Bβ (50 kDa) and γ (43 kDa)
linked by disulfide bonds. It can be hydrolyzed by
thrombin, thus producing fibrin components and fibri-
nopeptides. Thrombin activity (control) on fibrinogen
demonstrated the release of fibrinopeptide A (FpA)
followed by fibrinopeptide B (FpB).
Proteolytic enzymes of Cerastes cerastes venom were
identified as α, β or γ fibrinogenases depending on their
ability to hydrolyze the fibrinogen in vitro. SDS-PAGE
analysis of fibrinogen in the presence of venom revealed
two entities (55 kDa and 50 kDa) indicating activities of
α- and β-fibrinogenase. Purification and characterization
of three procoagulant proteinases (RP34, afaâcytin and
CC3-SPase proteinase) showed fibrinogenolytic activities
when analyzed by SDS-PAGE, afaâcytin and RP34
displayed, respectively, α,ß-fibrinogenase and α-fibrino-
genase activity [11,32,34]. Like afaâcytin, CC3-SPase is
also characterized as an α,β-fibrinogenase due to the re-
lease of both A and B fibrinopeptides.
Susceptibility of afaâcytin to diisopropyl fluoro-
phosphate and benzamidine indicates the presence of a
serine and an aspartic (or glutamic) acid residues in the
catalytic site. Calcium is required for structural cohesion
of the afaâcytin molecule [11]. CCSV-MPase cleaves only
the Bβ chain of fibrinogen and exerted no action on Aα
or γ chains. This property contrasts with those of other
SVMPs which preferentially cleave only the Aα-
fibrinogen chain. However, these metalloproteinases,
belonging to the PI class of SVMPs, present low molecu-
lar mass, with only the metalloproteinase domain, as inthe case of fibrolase purified from Akgistrodon contortrix
contortrix, piscivorase II of Akgistrodon piscivorus
piscivorus, lebetase purified from the venom of Vipera
lebetina, neuwiedase from Bothrops neuwiedi venom,
the atroxase of Crotalus atrox and leucurolysins from
venom of Bothrops leucurus [5,38-42].
Proteinases (afaâcytin, RP34, CC3-SPase and CCSV-
MPase) showed caseinolytic activity as crude venom. CC3-
SPase displayed arginine ester hydrolase activity while the
CCSV-MPase does not. Both molecules presented a high
amidolytic activity similar to that of crude venom. Previous
results revealed that the use of specific inhibitors for serine
proteinases and metalloproteinases showed that CC3-
SPase is a thrombin-like Ca2+-dependent serine proteinase.
Afaâcytin isolated from the venom of Cerastes cerastes
showed that Ca2+ is essential for its activity not only as a
cofactor but can contribute to the stability or structural
cohesion of the enzyme [11]. CCSV-MPase appears to be a
zinc-dependent metalloproteinase given that metal chela-
tors, EDTA and 1,10-phenanthroline completely inhibited
its proteolytic activity, which also suggested that unlike
CC3-SPase, Ca2+ is not required for its catalytic activity.
The sensitivity of the serine proteinase CC3-SPase, a
specific inhibitor of thrombin (heparin and antithrombin
III) may indicate that the receptor of CC3-SPase is identi-
cal to that of thrombin. Given its procoagulant properties
and insensitivity to thrombin-specific plasma inhibitors,
afaâcytin might be interesting to employ as a hemostatic
agent in some types of hemorrhage, such as post-operative
thrombocytopenia [11].
Serine-proteinases hydrolyze fibrinogen by acting on
the two chains, α and β, of this substrate thereby causing
the formation of a fragile fibrin clot. CCSV-MPase acts
on the β chain of fibrinogen resulting in the release of
only fibrinopeptide B. Afaâcytin, as a component of the
venom (2% w/w), hydrolyzes fibrinogen in the same
manner that CC3-SPase degrades firstly the Aα chain
and then, 24 hours later, the Bβ chain, leading to a fra-
gile clot, which suggests that CC3-SPase, similarly to
afaâcytin, is unable to activate the factor XIII responsible
for the resistance of the fibrin clot [11,34]. CCSV-MPase
cleaves only the Bβ chain of fibrinogen and exerts no ac-
tivity on Aα and γ chains. CCSV-MPase properties may
allow its use as a therapeutic agent in some pathologies
that require anticoagulant administration.
Most thrombin-like enzymes (TLE) isolated from
snake venoms act on fibrinogen by hydrolyzing one
chain rather than two, although the cleavage site is the
same (Arg16-Gly17) as the α chain (Arg15- Gly16) on β
chain, by releasing fibrinopeptides A or B as CCSV-
MPase which degrades only the β chain of fibrinogen.
CC3-SPase shortened the clotting time of plasma defi-
cient in factor VII and II with a weaker clot than that
formed with normal plasma. The clotting time of plasma
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normal plasma after the action of serine protease CC3-
SPase, which suggests that this molecule is able to re-
place factors IIa and VII.
Procoagulant and anticoagulant snake venom compo-
nents often act at later stages of the coagulation cascade.
The main targets of these components are fibrinogen,
prothrombin, factor X and platelets [3,5,11,12,17].
Several molecules have been purified from Viperidae
and Crotalidae venoms and characterized as FX activator
factors that are used as biomarkers in many hemostatic
disorders. Indeed, thrombin-like components serve as
structural models to extend our understanding of the
structure-function relationships of blood coagulation
factors, some of which have been clinically used for the
treatment of thrombotic diseases, and are employed as
tools in clinical assays [43].
Combination of gel filtration and ion-exchange chro-
matography proved to be successful in obtaining
milligram quantities of new pure TLEs from the venoms
of Crotalus durissus terrificus and Crotalus durissus
collilineatus [43]. Functional characterization indicates
that both enzymes preferentially degrade the Bβ chain of
bovine fibrinogen and present edema-inducing and
coagulant activities. However, the TLE from Crotalus
durissus collilineatus venom showed twofold higher co-
agulant activity with a minimum coagulant dose (MCD)
of 0.6 μg/μL, whereas the enzyme isolated from Crotalus
durissus terrificus indicated an MCD of 1.5 μg/μL [43].
Recently, a TLE denominated BpSP-I was isolated
from Bothrops pauloensis snake venom; its biochemical,
enzymatic and pharmacological characteristics were de-
termined. BpSP-I showed high clotting activity upon bo-
vine and human plasma and was inhibited by PMSF,
benzamidine and leupeptin. Moreover, this enzyme
showed stability when examined at different tempera-
tures (−70 to 37°C), pH values [3-9] or in the presence
of divalent metal ions (Ca2+, Mg2+, Zn2+ and Mn2+).
BpSP-I showed high catalytic activity upon substrates,
such as fibrinogen, TAME, S-2238 and S-2288. It also
showed kallikrein-like activity, but was unable to act
upon factor Xa or plasmin substrates [44].
Reducing blood viscosity is often required in the treatment
of thrombotic and ischemic heart diseases. Defibrinogenation
of the plasma by some enzymes from snake venoms is of
interest. Indeed, all of these defibrinogenating biomolecules
sharing these properties could be used as tools in clinical ap-
plications and in basic research. Further studies, in pharma-
cology and toxicology should be undertaken to determine
their mode of action in vivo.
Effect of molecules on platelet function
Biological characterization of CCSV-MPase and CC2-
PLA2 has been shown to be highly anti-aggregative inrelation to human platelets. The antagonistic effect of
CC3-SPase is of interest in the context of the antiplatelet
action of the hemostatic system, and may be an effective
tool for reducing blood viscosity, a property that is often
necessary in the treatment of thrombotic diseases and is-
chemic heart syndrome due to platelet aggregation. Pre-
vious studies have already demonstrated that afaâcytin
may replace the missing factors VIII and IX in deficient
plasmas, and activate purified human factor X into fac-
tor Xa [11]. It releases serotonin from platelets and dir-
ectly aggregates human (but not rabbit) blood platelets.
On the other hand, RP 34 has no effect on platelet ag-
gregation [32]. Several anticoagulant PLA2s from snake
venoms have been isolated and well characterized. Re-
cently, two phospholipases, known as CC-PLA2-1 and
CC-PLA2-2 with antiplatelet aggregation activity, were
isolated from Cerastes cerastes venom [45]. An anti-
coagulant PLA2 was isolated and characterized as an in-
hibitor of the prothrombinase complex through its
specific binding to FX [46]. Ammodytoxin A (Atxa) and
its natural ammodytoxin isoform C were isolated from
Vipera ammodytes ammodytes venom and belong to
group IIA secreted phosphoplipases. These two isoforms
differ only by two amino acid residues (Phe 124 > Ile
and Lys128 > Glu), but there are significant differences
in toxicity. The mechanism by which they block coagula-
tion has been elucidated. Complementary experiments
using surface plasmon resonance showed complete in-
hibition of binding to FXa through calmodulin (CaM).
The crystal structure showed that the C-terminal region
required for binding to FXa and CaM is highly exposed
and accessible for interaction with receptor proteins in
the monomeric and dimeric forms of ammodytoxin [45].
Conclusion
Viperidae venoms, considered to be one of the most im-
portant bioresources, include pharmacologically active
molecules such as proteinases (metalloproteinases and
serine proteinases) and phospholipase A2 [46,47]. All of
these molecules are of interest in biotherapy as biomedi-
cines or may be used as diagnostic tools. Proteases and
PLA2 act on the hemostatic system as procoagulants,
anticoagulants, and as agents of pro- or anti-platelet ag-
gregation. Some of these molecules, especially those iso-
lated from Viperidae venoms, are used in the diagnosis
and treatment of thrombotic and heart diseases. Some
components act synergistically at different stages of the
coagulation cascade [48].
Constituents of Viperidae venoms contain two categor-
ies of components that act antagonistically through activa-
tion or inhibition of coagulation factors and platelet
aggregation. These compounds, able to hydrolyze the co-
agulation factors with high specificity, are divided into
serine proteinases and metalloproteinases. Phospholipases
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molecules of snake venoms are of great fundamental
diagnostic and therapeutic interest. Therapeutically,
proteinases from Viperidae venoms are widely used as an-
ticoagulants. Furthermore, they are valuable tools for un-
derstanding the different mechanisms of hemostasis and
are also used in the diagnosis of dysfunctions related to
coagulation factors such as enzyme activity in thrombin-
like venoms that are used for the fibrinogenopathy screen-
ing. Venoms are also used for diagnostic analysis of vari-
ous coagulation factors (factors V, VII, X, platelet factor
III, protein C and factor of Willbrand). Snake venom pro-
teases are useful tools for studying coagulation reactions.
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